Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally found lead drug candidate. With the IPO proceeds, Odyssey plans mid-stage medical trials evaluating the small molecule together with Takeda’s Entyvio and as a monotherapy.
The put up Odyssey’s IPO Brings In $304M for Quest to Develop Higher Immunology Medication appeared first on MedCity Information.
